First-line oral therapies
Teriflunomide (Aubagio) is a metabolite of leflunomide, a long-established DMT in rheumatoid arthritis. It is thought to inhibit dihydro-orotatedehydrogenase, an enzyme necessary for pyrimidine synthesis in actively dividing cells. 19 Phase III trials confirmed a relative reduction in annualised relapse rate (ARR) of 31.5-36.3%, and of progression of disability of 29.8-31.5% compared with placebo. [20] [21] At the UK licensed dose of 14mg once daily, teriflunomide has an acceptable side-effect profile which, with its efficacy, places it alongside the injectable therapies. Teriflunomide is approved by NICE for active, but not highly active or rapidly evolving severe MS. 22 Common side-effects include hair thinning, which is usually transient, and elevated liver enzymes. [19] [20] [21] 23 Liver function tests, as well as a full blood count and blood pressure, should be monitored during treatment. 19 Teriflunomide is strictly contraindicated in pregnancy and a negative pregnancy test should be confirmed prior to commencement of therapy. 19, 24 Due to teriflunomide's long half-life of 15-18 days, activated charcoal or cholestyramine is required to eliminate the drug in a reasonable time frame. 24 Dimethyl fumarate The active ingredient of dimethyl fumarate (DMF, Tecfidera) has previously been used in treatments for psoriasis. 25 Two phase III trials, DEFINE and CONFIRM, demonstrated a relative reduction of ARR of 44-53% with twice-daily DMF 240mg compared with placebo, and so DMF is also approved by NICE for active relapsing MS. [26] [27] [28] DMF is speculated to cross the blood / brain barrier and exert neuroprotective effects, potentially on myelin. 25, 29 However, while the two pivotal trials (DEFINE and CONFIRM) demonstrated significantly fewer gadolinium-enhancing lesions, T2 lesions and T1 hypointense lesions in DMF twice daily compared with placebo, DMF does not significantly reduce brain atrophy, 30 and the 38% relative reduction in sustained disability in the DEFINE trial was not replicated by CONFIRM. [26] [27] A troublesome side-effect is gastrointestinal disturbance and flushing. This usually abates, and can be eased by taking with food and gradual up-titration of dose. 25, 29 Monitoring requirements include a full blood count six-eight weekly, as cases of progressive multifocal leucoencephalopathy (PML) have been linked to prolonged lymphopaenia. 25, [31] [32] Nevertheless, PML, a potentially fatal demyelinating brain disease caused by reactivation and replication in oligodendrocytes of the JC virus, remains most recognised secondary to natalizumab (Tysabri) treatment. 33 
Second-line oral therapy
Fingolimod When approved by NICE in 2012, fingolimod (Gilenya) was the first oral MS therapy. It is approved in the UK for highly active relapsing-remitting disease which has not responded to interferons and is taken once daily at a dose of 0.5mg. 34 Fingolimod is an inactive prodrug but is phosphorylated and causes internalisation of S1P receptors, which are required for lymphocyte trafficking. [35] [36] Lymphocytes remain in nodes and are restrained from sites of central nervous system (CNS) inflammation. 35 As fingolimod crosses the blood / brain barrier, a neuroprotective effect was hoped for via interaction with S1P receptors on glial cells and oligodendrocytes, but negative results from a study in primary progressive MS were recently announced. [36] [37] [38] In phase III testing, fingolimod achieved 48-54% relative reduction in ARR in two placebo-controlled trials, and a 52% relative reduction in ARR compared with an active comparator, intramuscular interferon. [39] [40] [41] Two of the phase III trials did not show a significant impact on disability measures, [40] [41] whereas in the FREEDOMS I placebo-controlled study, there was a 30% reduction in confirmed disability at 24 months and a 30% slowing in brain atrophy among fingolimod patients. 39 Set against these results is an active side-effect profile, which, as well as first dose bradycardia, includes first and second degree atrioventricular block, macular oedema, lymphophenia and infections. [39] [40] [41] Therefore ECG pre-and post-first dose is indicated. 14 Ophthalmologic monitoring is required during treatment and patients should have varicella immunity, 14 although a case of varicella encephalitis was recently reported in an immunised fingolimod patient. 42 To date, 3 cases of PML have been reported in patients using fingolimod; however a precise risk of this rare complication remains to be determined and clinicians should remain vigilant. 43 
Infusion therapies
Natalizumab was approved by NICE in 2007 for REMS (rapidly evolving severe RRMS) and is given as an IV infusion at 300mg every 28 days. 44 It is a monoclonal antibody to the a4β1 integrin molecule on lymphocyte membranes. Through the interaction of this molecule with vascular cell adhesion molecule 1 (VCAM1), lymphocytes are able to attach to and penetrate the blood/brain barrier. 45 It follows that blocking this interaction reduces CNS inflammation.
Accordingly, the phase III AFFIRM trial found that, compared to placebo patients, those on Natalizumab had a relative reduction of 68% in relapse rate at one year and of 42% in the risk of acquiring a permanent increase in disability at two years. 46 These clinical findings were supported by MRI data which at two years revealed the natalizumab group to benefit from a relative reduction of 92% in gadolinium-enhancing lesions and 83% in T2 lesions. 46 No head-to-head trial against a direct comparator was performed prior to licensing, but in 2012 a retrospective cohort study comparing natalizumab to IFNβ-1a 44mg concluded natalizumab was more effective on measures of ARR, disability progression and enhancing lesions. 47 Efficacy of Natalizumab must be balanced alongside the risk of natalizumab-associated PML. More than 500 cases of natalizumab-associated PML, Abbreviations: CIS = clinically isolated syndrome; EDSS = Expanded disability status scale; IM = intramuscular; SAD = sustained accumulation of disability; s/c = subcutaneous; RR = relative reduction Alemtuzumab In May 2014 Alemtuzumab (Lemtrada) was granted a wide scope of use by NICE, which recommended it for use in active RRMS. 51 A humanised anti-CD52 monoclonal antibody, it works through pan-lymphocyte depletion and immune reconstitution with re-skewing of the immune repertoire. 52 It is given annually as an infusion of 12mg/day for five days in year one and three days in year two, with methylprednisolone given concurrently to alemtuzumab infusion. 52 Most patients require only two cycles for stabilisation of disease activity. 52 Notably, phase II and phase III trials have all been performed against an active comparator, subcutaneous IFN β-1a 44mg. In the phase II CAMS223 trial, alemtuzumab 12mg at 36 months produced a 75% reduction in the risk of sustained disability and a 69% reduction in relapse compared with IFN β-1a 44mg. 53 Additionally, alemtuzumab patients demonstrated a 0.39 points improvement on the Expanded Disability Status Scale (EDSS) and increased brain volume. 53 Countering these results, enhanced pharmacovigilance was implemented after one patient died of a brain haemorrhage secondary to immune thrombocytopaenic purpura (ITP). 53 Phase III trials confirmed a 49.4 (previously treated patients)-54.9% (treatment naïve individuals) reduction in ARR compared with IFNβ -1a 44mg. [54] [55] In previously treated patients, there was also a 42% reduction in the risk of acquiring fixed disability. 55 Both trials found significant differences in favour of alemtuzumab in the number of new or enlarging T2 lesions, gadolinium enhancing lesions and the rate of brain atrophy. [54] [55] Emerging four-year data from these trials have demonstrated 79.3% of treatment naïve and 67% of previously treated patients with stable or improved EDSS at four years. [56] [57] Alemtuzumab is associated with an infusion reaction, which can be managed by concurrent administration of steroid, antihistamine and antipyretic. 58 However, the principal side-effects are secondar y 52, 58 This is principally thyroid related, but ITP and Goodpasture syndrome remain key safety concerns. 52, 58 Therefore, patients must be able to comply with a strict monitoring programme of regular blood tests. 58 As conception can be attempted four months post infusion, alemtuzumab may represent a useful option for individuals planning a family. 58 Mitoxantrone has not been assessed by NICE but is indicated in the 2009 ABN guidelines for rapidly evolving MS; in clinical practice its principal role is in worsening secondary progressive disease with evidence of inflammatory activity on MRI. 5 A Cochrane review concluded the drug was efficacious in reducing ARR, progression of disability and radiological evidence of disease in worsening RRMS and SPMS. 59 A cytotoxic drug borrowed from the oncology setting, mitoxantrone interferes with DNA replication in rapidly dividing cells. 59 It is prescribed as an induction therapy, with two protocols developed; in the UK, the Edan protocol, with monthly infusions for six months, followed by an alternate immunomodulatory drug, is preferred. 60 Mitoxantrone carries a significant side-effect profile. Due to risk of cardiotoxicity, there is a strict weightbased dosing limit with an absolute ceiling of 140mg/m 2 . 59 However, outside of oncological practice a lower ceiling dose -in France, where it holds a licence in MS, of around 70mg/m 2 -is applied. 60 This is relevant as cardiotoxicity is dose-related; baseline ECG and echocardiogram should be obtained, and mitoxantrone is contraindicated where left ventricular ejection fraction is less than 50%. 61, 62 Another important consideration is treatment-related acute myeloid leukaemia, which was recently found to affect as many as 27% and carry a 37% mortality rate in an Italian cohort. 63 Mitoxantrone can cause infertility and amenorrhoea and is contra-indicated in pregnancy. [60] [61] [62] Future therapies Daclizumab is a humanised CD25 monoclonal antibody currently in phase III development. As the first MS immunotherapy whose prinicipal mechanism may be through the innate, not the adaptive, immune system, daclizumab is an interesting addition to the debate on the biology of MS. 64 It is given as a subcutaneous injection with a dose of 150mg once monthly currently under evaluation. 65 Phase III results are awaited, but recently released imaging results suggested a positive impact on brain atrophy as well as on gadolinium-enhancing, T2 and T1 hypointense lesions compared to intramuscular interferon β-1a. 66 In phase II testing, compared with placebo, daclizumab had achieved a 54% relative reduction of ARR and a 57% relative reduction in risk of sustained disability at one year. 65 Skin reactions and rashes are a common side-effect, and one patient died in the phase II trial while recovering from a severe rash. 64, 65 Surveillance has been stepped up, and enhanced skin care, including use of sunscreen and emollients, is recommended. 64 Humoral therapies The success of clinical trials of B-cell directed therapies argues for a contribution of humoral immunity in MS. Rituximab, an anti-CD20 monoclonal antibody targeting B-cells, was shown to reduce the number of gadolinium enhancing lesions by 91% compared with placebo in the phase II HERMES trial in RRMS, and reduced the number of patients with relapse by 50%. 67 Despite these beneficial results, rituximab, which is coming off patent, is not currently being carried forward into phase IIl trials.
Review
However, manufacturer Roche is developing a successor molecule. Ocrelizumab is an anti-CD20 monoclonal antibody, but fully humanised and predicted to increase therapeutic efficacy and reduce immunogenicity. 68 In a phase II trial, ocrelizumab in two different infusion regimes achieved 89-96% reduction in gadolinium enhancing lesions and 80-73% reduction in relapse rate. 68 Laquinimod Marketing authorisation for laquinimod was recently declined by the European Medicines Agency, 69 despite one phase III trial showing a 33% reduction in ARR compared with placebo, and results from this and a second phase III study demonstrating impact on disability progression and brain atrophy. [70] [71] Manufacturer Teva is pursuing a new phase III trial which will focus on disability and brain atrophy measures and it is hoped the drug may have a future role as a neuroprotective agent. 72 
Old drugs, new tricks?
The discovery that excess CNS sodium is implicated in MS disease progression has led to interest in sodium channel blockers. 73 Recruitment is ongoing for a trial (NCT01451593) which will examine whether phenytoin has a neuroprotective effect in patients presenting with optic neuritis. 74 Another sodium-channel blocker already in clinical use, amiloride, is one of three 'repurposed' drugs to be evaluated in the MS-SMART trial in SPMS (NCT01910259). 75 Riluzole, an antiglutamatergic drug currently licensed in motor neuron disease, and Fluoxetine, an antidepressant in the selective seratonin reuptake inhibitor (SSRI) class, are the other two to be studied. 75 Statins are well known from the cardiovascular setting and a placebo-controlled phase II trial of high-dose simvastatin (80mg) in SPMS recently reported a positive effect on brain atrophy and disability progression. 76 While the idea of introducing known therapies with predictable safety records into MS clinical practice is attractive, practicalities around funding of large-scale phase III trials and management of the licensing process remain to be addressed. 77 This was recently illustrated by the withdrawal of the marketing licence application for oral cladribine by its manufacturer Merck Serono, 78 despite a phase III trial showing a 54.5-57.6% reduction in relapse rate. 79 
Conclusions
The MS DMT armamentarium has greatly expanded in recent years and a number of therapies are in the pipeline. This expansion has provided both patient benefit and insights into the aetiology of MS. With DMTs recommended in active and highly active relapsing disease, future phase III trials should employ an active comparator. The relatively short (two to three year) timespan of most pivotal trials is a hurdle to examining the long-term effect on disease progression in a lifelong condition. Although there are data over as long as 16 years from the first DMTs, 80 this is an unlikely area of expansion for commercial clinical trials. Inclusion of additional disability outcomes alongside the traditional EDSS, such as cognitive and upper limb function, may be more sensitive to detect impact on disease progression in future trial cohorts. 81 A pragmatic approach using data registries, for example the MSBase registry project, can also address areas of research need such as head-to-head comparisons and long-term follow up. 82 The emergence of PML after the adoption of natalizumab into clinical practice remains a salutary lesson on patient safety, further emphasised by cases in DMF and fingolimod patients. Individual risk and benefit should be carefully weighed up as part of the decision-making process to match DMT to level of clinical MS activity. For individuals with aggressive disease, careful vigilance and stratification can minimise but not eliminate the risks accompanying potent immunotherapies. Future directions include molecules with new mechanisms of action, those with putative neuroprotective effects and combination therapy. 
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